Michael J Duffy

Summary

Affiliation: University College Dublin
Country: Ireland

Publications

  1. ncbi request reprint The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
  2. pmc Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer
    B Ryan
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Br J Cancer 92:120-4. 2005
  3. pmc Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA
    E McKiernan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Br J Cancer 99:1644-50. 2008
  4. pmc Overexpression of the Ets-1 transcription factor in human breast cancer
    Y Buggy
    Department of Surgery, University College Dublin, St Vincent s University Hospital, Dublin 4, Ireland
    Br J Cancer 91:1308-15. 2004
  5. doi request reprint The war on cancer: are we winning?
    M J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Tumour Biol 34:1275-84. 2013
  6. doi request reprint Tumor markers in clinical practice: a review focusing on common solid cancers
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Med Princ Pract 22:4-11. 2013
  7. doi request reprint Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
  8. ncbi request reprint The ADAMs family of proteins: from basic studies to potential clinical applications
    Michael J Duffy
    Dept of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Thromb Haemost 89:622-31. 2003
  9. ncbi request reprint High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 50:559-63. 2004
  10. doi request reprint Methylated genes as new cancer biomarkers
    M J Duffy
    Department of Pathology and Laboratory Medicine, Nuclear Medicine Laboratory, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Eur J Cancer 45:335-46. 2009

Detail Information

Publications82

  1. ncbi request reprint The urokinase plasminogen activator system: role in malignancy
    Michael J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Curr Pharm Des 10:39-49. 2004
    ..Finally, preclinical studies show that either inhibition of uPA catalytic activity or prevention of uPA binding to its receptor reduces tumor growth, angiogenesis and metastasis...
  2. pmc Expression of survivin and its splice variants survivin-2B and survivin-DeltaEx3 in breast cancer
    B Ryan
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Br J Cancer 92:120-4. 2005
    ..Our results suggest that the different forms of survivin may have different roles in apoptosis in breast cancer...
  3. pmc Protein kinase Cdelta expression in breast cancer as measured by real-time PCR, western blotting and ELISA
    E McKiernan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Br J Cancer 99:1644-50. 2008
    ..007, Mann-Whitney U-test). Increasing concentrations of PKCdelta mRNA were associated with reduced overall patient survival (P=0.004). Our results are consistent with a role for PKCdelta in breast cancer progression...
  4. pmc Overexpression of the Ets-1 transcription factor in human breast cancer
    Y Buggy
    Department of Surgery, University College Dublin, St Vincent s University Hospital, Dublin 4, Ireland
    Br J Cancer 91:1308-15. 2004
    ..Since p52, p51 and p33 correlate with uPA levels, these forms of Ets-1 may play a role in breast cancer metastasis...
  5. doi request reprint The war on cancer: are we winning?
    M J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Tumour Biol 34:1275-84. 2013
    ..With continued basic and clinical research, cancer is being transformed into a chronic disease in which patients have increased survival rates and better quality of life...
  6. doi request reprint Tumor markers in clinical practice: a review focusing on common solid cancers
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Med Princ Pract 22:4-11. 2013
    ..Although widely used, the value of prostate-specific antigen screening in reducing mortality from prostate cancer is unclear...
  7. doi request reprint Targeted therapy for triple-negative breast cancer: where are we?
    Michael J Duffy
    UCD Clinical Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 131:2471-7. 2012
    ..The rational way forward for treating these patients is likely to be biomarker-driven, combination targeted therapies or combination of targeted therapy with cytotoxic chemotherapy...
  8. ncbi request reprint The ADAMs family of proteins: from basic studies to potential clinical applications
    Michael J Duffy
    Dept of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Thromb Haemost 89:622-31. 2003
    ..Altered expression of certain ADAMs has been associated with a number of diseases including asthma, arthritis, Alzheimer's disease, atherosclerosis and cancer...
  9. ncbi request reprint High preoperative CA 15-3 concentrations predict adverse outcome in node-negative and node-positive breast cancer: study of 600 patients with histologically confirmed breast cancer
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 50:559-63. 2004
    ..CA 15-3 is the most widely used serum marker in breast cancer. Currently, its main uses are in the surveillance of patients with diagnosed disease and monitoring the treatment of patients with advanced disease...
  10. doi request reprint Methylated genes as new cancer biomarkers
    M J Duffy
    Department of Pathology and Laboratory Medicine, Nuclear Medicine Laboratory, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Eur J Cancer 45:335-46. 2009
    ..It is concluded that methylated genes have the potential to provide a new generation of cancer biomarkers...
  11. ncbi request reprint Evidence for the clinical use of tumour markers
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Ann Clin Biochem 41:370-7. 2004
    ..Although currently in widespread use, the value of prostate-specific antigen in screening for prostate cancer has yet to be validated in a large prospective randomized trial...
  12. ncbi request reprint Estrogen receptors: role in breast cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Crit Rev Clin Lab Sci 43:325-47. 2006
    ..Further work is required to establish if ERbeta has a clinical role in breast cancer...
  13. ncbi request reprint A personalized approach to cancer treatment: how biomarkers can help
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 54:1770-9. 2008
    ..This practice is inefficient and frequently results in inappropriate therapy and treatment-related toxicity. In contrast, personalized treatment has the potential to increase efficacy and decrease toxicity...
  14. ncbi request reprint CA125 in ovarian cancer: European Group on Tumor Markers guidelines for clinical use
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Gynecol Cancer 15:679-91. 2005
    ..CA125 is the ovarian cancer marker against which new markers for this malignancy should be judged...
  15. ncbi request reprint Cancer invasion and metastasis: changing views
    M J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    J Pathol 214:283-93. 2008
    ..These recent advances in our understanding should lead to the development of new molecular markers for predicting the likely formation of metastasis as well as the identification of new targets for anti-metastatic therapies...
  16. ncbi request reprint Tumour markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines for clinical use
    M J Duffy
    Department of Pathology and Laboratory Medicine, Nuclear Medicine Laboratory, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Eur J Cancer 43:1348-60. 2007
    ..Faecal occult blood testing but not faecal DNA markers may be used to screen asymptomatic subjects 50 years or older for early CRC...
  17. ncbi request reprint Serum tumor markers in breast cancer: are they of clinical value?
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 52:345-51. 2006
    ..29 (CA27.29), carcinoembryonic antigen (CEA), tissue polypeptide antigen, tissue polypeptide specific antigen, and HER-2 (the extracellular domain), the most widely used are CA 15-3 and CEA...
  18. ncbi request reprint Clinical utility of biochemical markers in colorectal cancer: European Group on Tumour Markers (EGTM) guidelines
    M J Duffy
    Department of Surgery, Conway Institute of Biomolecular and Biomedical Research, University College Dublin 4 and Nuclear Medicine, St Vincent s University Hospital, 4, Dublin, Ireland
    Eur J Cancer 39:718-27. 2003
    ..Similarly, the new cell and tissue-based markers (e.g, ras, P53) cannot yet be recommended for routine clinical use...
  19. doi request reprint Role of ADAMs in cancer formation and progression
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Clin Cancer Res 15:1140-4. 2009
    ..The ADAMs are thus a new family of potential targets for the treatment of cancer, especially malignancies that are dependent on human epidermal growth factor receptor ligands or tumor necrosis factor-alpha...
  20. pmc Metalloproteinases: role in breast carcinogenesis, invasion and metastasis
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Breast Cancer Res 2:252-7. 2000
    ..Because MMPs are apparently involved in breast cancer initiation and dissemination, inhibition of these proteinases may be of value both in preventing breast cancer and in blocking metastasis of established tumours..
  21. doi request reprint Prostate-specific antigen: does the current evidence support its use in prostate cancer screening?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Ann Clin Biochem 48:310-6. 2011
    ..Newly emerging markers that may complement PSA in the early detection of prostate cancer include specific isoforms of PSA and PCA3...
  22. pmc The ADAMs family of proteases: new biomarkers and therapeutic targets for cancer?
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St, Vincent s University Hospital, Dublin 4, Ireland
    Clin Proteomics 8:9. 2011
    ..Furthermore, a number of selective ADAM inhibitors, especially against ADAM10 and ADAM17, have been shown to have anti-cancer effects. At least one of these inhibitors is now undergoing clinical trials in patients with breast cancer...
  23. doi request reprint Use of faecal markers in screening for colorectal neoplasia: a European group on tumor markers position paper
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin and UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Int J Cancer 128:3-11. 2011
    ....
  24. doi request reprint CA 15-3: uses and limitation as a biomarker for breast cancer
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 411:1869-74. 2010
    ..The main limitation of CA 15-3 as a marker for breast cancer is that serum levels are rarely increased in patients with early or localized disease...
  25. doi request reprint Use of molecular markers for predicting therapy response in cancer patients
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Cancer Treat Rev 37:151-9. 2011
    ..The availability of predictive markers should increase drug efficacy and decrease toxicity, thus leading to a more personalized approach to cancer treatment...
  26. ncbi request reprint Urokinase-type plasminogen activator: a potent marker of metastatic potential in human cancers
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Biochem Soc Trans 30:207-10. 2002
    ..e. in both a randomized prospective trial and a pooled analysis. Therefore, uPA and PAI-1 appear to have fulfilled all the criteria for the routine assessment of prognosis in newly diagnosed breast cancer patients...
  27. ncbi request reprint Urokinase plasminogen activator and its inhibitor, PAI-1, as prognostic markers in breast cancer: from pilot to level 1 evidence studies
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chem 48:1194-7. 2002
    ..The primary determinant of outcome in malignancy is the formation of distant metastases. Urokinase plasminogen activator (uPA) is a serine protease causally involved in invasion and metastasis...
  28. doi request reprint Tumor markers in pancreatic cancer: a European Group on Tumor Markers (EGTM) status report
    M J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin
    Ann Oncol 21:441-7. 2010
    ..CA 19-9 thus remains the serum pancreatic cancer marker against which new markers for this malignancy should be judged...
  29. ncbi request reprint The role of ADAMs in disease pathophysiology
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chim Acta 403:31-6. 2009
    ..Further work is required in order to establish a causative role for ADAMs in rheumatoid arthritis, Alzheimer's disease, cardiac hypertrophy and asthma...
  30. ncbi request reprint Biochemical markers in breast cancer: which ones are clinically useful?
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Biochem 34:347-52. 2001
    ....
  31. ncbi request reprint Carcinoembryonic antigen as a marker for colorectal cancer: is it clinically useful?
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chem 47:624-30. 2001
    ..Its main application is mostly in gastrointestinal cancers, especially in colorectal malignancy. Although in use for almost 30 years, the clinical value of CEA in colorectal cancer is still not clear...
  32. ncbi request reprint Mammaglobin a in breast cancer: existence of multiple molecular forms
    Neil A O'Brien
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 114:623-7. 2005
    ..As expression of MGA is almost breast specific, it is a promising marker for breast cancer. Its most immediate use is likely to be in detecting micrometastases from breast cancer...
  33. ncbi request reprint Increased claudin-4 expression is associated with poor prognosis and high tumour grade in breast cancer
    Fiona Lanigan
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Dublin, Ireland
    Int J Cancer 124:2088-97. 2009
    ..We conclude that high levels of claudin-4 protein are associated with adverse outcome in breast cancer patients, including the subgroup of patients treated with adjuvant tamoxifen...
  34. pmc Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer
    Elton Rexhepaj
    UCD Conway Institute, University College Dublin, Belfield, Ireland
    BMC Cancer 10:639. 2010
    ..Here, we validate survivin CNR in a separate and extended cohort. Furthermore, we present new data suggesting that a low CNR may predict outcome in tamoxifen-treated patients...
  35. ncbi request reprint Lipophilin B: A gene preferentially expressed in breast tissue and upregulated in breast cancer
    Jane Culleton
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Cancer 120:1087-92. 2007
    ..Since LPB was expressed relatively specifically in breast tissue and was significantly upregulated in breast carcinomas, it is a promising candidate biomarker for breast cancer...
  36. pmc Novel image analysis approach for quantifying expression of nuclear proteins assessed by immunohistochemistry: application to measurement of oestrogen and progesterone receptor levels in breast cancer
    Elton Rexhepaj
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Belfield, Ireland
    Breast Cancer Res 10:R89. 2008
    ..In the present article we describe the development of a novel approach for automatically quantifying oestrogen receptor (ER) and progesterone receptor (PR) protein expression assessed by IHC in primary breast cancer...
  37. ncbi request reprint Altered cytoplasmic-to-nuclear ratio of survivin is a prognostic indicator in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science and UCD School of Medicine and Medical Science, UCD Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Clin Cancer Res 14:2681-9. 2008
    ..Quantitative determination of survivin expression using image analysis offers the opportunity to develop alternative scoring models for survivin immunohistochemistry. Here, we present such a model...
  38. ncbi request reprint CENP-F expression is associated with poor prognosis and chromosomal instability in patients with primary breast cancer
    Sallyann L O'Brien
    UCD School of Biomolecular and Biomedical Science, Conway Institute, University College Dublin, Belfield, Dublin, Ireland
    Int J Cancer 120:1434-43. 2007
    ..036) and overall survival (p=0.040). In conclusion, we identified CENP-F as a biomarker associated with poor outcome in breast cancer and showed several novel associations of biological significance...
  39. ncbi request reprint Use of a panel of novel genes for differentiating breast cancer from non-breast tissues
    Deirdre Foley
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin, Ireland
    Tumour Biol 28:312-7. 2007
    ..Genes such as MGA, B726P and SBEM that are expressed relatively exclusively in breast tissue are potential new markers for breast cancer...
  40. ncbi request reprint Caspase 3 in breast cancer
    Norma O'Donovan
    Department of Medical Oncology, St Vincent s University Hospital, University College Dublin, Dublin 4, Ireland
    Clin Cancer Res 9:738-42. 2003
    ..One of the key mediators of apoptosis is the thiol protease caspase 3. In this investigation, caspase 3 mRNA and protein expression in breast cancer was examined...
  41. ncbi request reprint ADAM-17 expression in breast cancer correlates with variables of tumor progression
    Patricia M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 13:2335-43. 2007
    ..524, P < 0.0001, n = 73 and active form: r = 0.365, P = 0.002, n = 73). Our results support the hypothesis that ADAM-17 is involved in breast cancer progression...
  42. ncbi request reprint CA IX is an independent prognostic marker in premenopausal breast cancer patients with one to three positive lymph nodes and a putative marker of radiation resistance
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College, Dublin, and Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Ireland
    Clin Cancer Res 12:6421-31. 2006
    ..We examined the potential prognostic and predictive role of CA IX in premenopausal breast cancer patients...
  43. ncbi request reprint Expression of ADAM-9 mRNA and protein in human breast cancer
    Caroline O'Shea
    Conway Institute of Biomolecular and Biomedical Sciences, University College Dublin, Dublin, Ireland
    Int J Cancer 105:754-61. 2003
    ..05) and correlated positively with HER-2/neu protein levels (r = 0.313, p = 0.016). This is the first report to describe expression of any ADAM in a large number of human carcinomas...
  44. ncbi request reprint Mammaglobin a: a promising marker for breast cancer
    Neil O'Brien
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Chem 48:1362-4. 2002
  45. ncbi request reprint Expression of the breast cancer metastasis suppressor gene, BRMS1, in human breast carcinoma: lack of correlation with metastasis to axillary lymph nodes
    Louise M Kelly
    Department of Surgery, Medical Oncology and Nuclear Medicine, St Vincent s University Hospital and Conway Institute for Biomolecular and Biomedical Research, University College Dublin, Dublin, Ireland
    Tumour Biol 26:213-6. 2005
    ..Our results do not suggest a role for BRMS1 in suppressing metastasis to local lymph nodes in patients with breast cancer...
  46. pmc Comparative antiproliferative effects of iniparib and olaparib on a panel of triple-negative and non-triple-negative breast cancer cell lines
    Aisling Pierce
    Education and Research Centre, St Vincent s University Hospital, Dublin, Ireland
    Cancer Biol Ther 14:537-45. 2013
    ..e., whether HER2-positive, estrogen receptor (ER)-positive or triple-negative. Olaparib, in combination with a selective CDK1 inhibitor or a pan HER inhibitor, is a potential new approach for treating breast cancer...
  47. pmc CA 15-3 is predictive of response and disease recurrence following treatment in locally advanced breast cancer
    Dhafir Al-azawi
    Department of Surgery, St, Vincent s University Hospital, Dublin, Ireland
    BMC Cancer 6:220. 2006
    ..Primary chemotherapy (PC) is used for down-staging locally advanced breast cancer (LABC). CA 15-3 measures the protein product of the MUC1 gene and is the most widely used serum marker in breast cancer...
  48. doi request reprint Prioritization of candidate protein biomarkers from an in vitro model system of breast tumor progression toward clinical verification
    Thomas Y K Lau
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute, University College Dublin, Ireland
    J Proteome Res 9:1450-9. 2010
    ..This approach provides a pragmatic approach to prioritizing candidates that may be most suitable for downstream assays such as multiple reaction monitoring...
  49. ncbi request reprint Contribution of DNA and tissue microarray technology to the identification and validation of biomarkers and personalised medicine in breast cancer
    Donal J Brennan
    UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, and Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Cancer Genomics Proteomics 4:121-34. 2007
    ..Here, we review the role of DNA microarrays and tissue microarrays in the validation of biomarkers in breast cancer, with emphasis on their potential application to determine mode of personalised therapy in the future...
  50. ncbi request reprint Levels of specific glycans significantly distinguish lymph node-positive from lymph node-negative breast cancer patients
    Aisling Pierce
    UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Glycobiology 20:1283-8. 2010
    ..As high levels of these glycans were associated with nodal metastases, their measurement may provide a new non-invasive approach to determining prognosis in women with newly diagnosed breast cancer...
  51. ncbi request reprint Predictive markers in breast and other cancers: a review
    Michael J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Clin Chem 51:494-503. 2005
    ..Unpredictable efficacy and toxicity are hallmarks of most anticancer therapies. Predictive markers are factors that are associated with response or resistance to a particular therapy...
  52. ncbi request reprint Survivin: a promising tumor biomarker
    Michael J Duffy
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Cancer Lett 249:49-60. 2007
    ..Furthermore, assays for the measurement of survivin should be simplified, standardized and evaluated in external quality assurance schemes...
  53. pmc Systematic antibody generation and validation via tissue microarray technology leading to identification of a novel protein prognostic panel in breast cancer
    Patrick C O Leary
    UCD School of Biomolecular and Biomedical Science, UCD Conway Institute of Biomolecular and Biomedical Science, University College Dublin, Dublin 4, Ireland
    BMC Cancer 13:175. 2013
    ....
  54. doi request reprint The role of S100 genes in breast cancer progression
    Eadaoin McKiernan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Tumour Biol 32:441-50. 2011
    ..Based on our findings, we conclude that the different S100 genes play varying roles in breast cancer progression. Specific S100 genes are potential targets for the treatment of basal-type breast cancers...
  55. ncbi request reprint Matrix metalloproteinase expression and outcome in patients with breast cancer: analysis of a published database
    P M McGowan
    Department of Pathology and Laboratory Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Ann Oncol 19:1566-72. 2008
    ..These MMPs are likely to be involved in mediating breast cancer progression and may thus be good targets for designing specific MMP inhibitors for the treatment of breast cancer...
  56. ncbi request reprint Studies on oestrogen receptor-alpha and -beta mRNA in breast cancer
    R Cullen
    Department of Nuclear Medicine, St. Vincent's University Hospital, Dublin, Ireland
    Eur J Cancer 37:1118-22. 2001
    ..We conclude that the presently used enzyme-linked immunosorbent assay (ELISA) for ER appears to be mostly measuring ER-alpha and is unlikely to be detecting ER-beta...
  57. doi request reprint Companion biomarkers: paving the pathway to personalized treatment for cancer
    Michael J Duffy
    UCD School of Medicine and Medical Science, Conway Institute, University College Dublin, Ireland
    Clin Chem 59:1447-56. 2013
    ..In this article we review the role of companion biomarkers in guiding treatment in patients with cancer...
  58. pmc Exploring the glycosylation of serum CA125
    Radka Saldova
    NIBRT GlycoScience Group, National Institute for Bioprocessing Research and Training, Mount Merrion, Blackrock, Dublin 4, Ireland
    Int J Mol Sci 14:15636-54. 2013
    ..Measurement of the glycosylated state of CA125 may therefore provide a more specific biomarker for patients with ovarian cancer. ..
  59. doi request reprint Intracellular and extracellular microRNAs in breast cancer
    Claire Corcoran
    School of Pharmacy and Pharmaceutical Sciences and Molecular Therapeutics for Cancer Ireland MTCI, Trinity College Dublin, Dublin, Ireland
    Clin Chem 57:18-32. 2011
    ..Toward this goal, it is essential to identify and understand the most relevant panels of biomarkers, some of which may also have relevance as therapeutic targets...
  60. ncbi request reprint The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin 4, Ireland
    Clin Biochem 37:541-8. 2004
    ..The measurement of uPA components, especially in breast cancer, thus has the potential to help with individualised patient management...
  61. ncbi request reprint Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1
    B M Ryan
    School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Dublin 4, Ireland
    Ann Oncol 17:597-604. 2006
    ..In this study we (a) evaluated the association between survivin and HER2, vascular endothelial growth factor (VEGF) and uPA/PAI-1 expression and (b) defined its effect on clinical outcome in a large breast cancer patient cohort...
  62. pmc Neratinib overcomes trastuzumab resistance in HER2 amplified breast cancer
    Alexandra Canonici
    National Institute for Cellular Biotechnology, Dublin City University, Dublin, Ireland
    Oncotarget 4:1592-605. 2013
    ....
  63. ncbi request reprint Application of DNA microarray technology in determining breast cancer prognosis and therapeutic response
    Donal J Brennan
    Conway Institute of Biomolecular and Biomedical Research, Department of Pharmacology, Centre for Molecular Medicine, University College Dublin, Dublin 4, Ireland
    Expert Opin Biol Ther 5:1069-83. 2005
    ..The most recent data supporting the integration of various publicly available data sets is also reviewed in detail...
  64. ncbi request reprint Breast cancer proteomics: clinical perspectives
    Thomas Y K Lau
    UCD Conway Institute, UCD School of Biomolecular and Biomedical Science, University College Dublin, Belfield, Dublin 4, Ireland
    Expert Opin Biol Ther 7:209-19. 2007
    ..It aims to analyse the complex circuitry of the breast cancer proteome. Here, the authors review how breast cancer proteomics has progressed so far, with emphasis on its potential application to clinically relevant scenarios...
  65. ncbi request reprint Objective measurement of breast cancer oestrogen receptor status through digital image analysis
    R Mofidi
    Department of Vascular Surgery, St Vincent s University Hospital, Elm Park, Dublin 4, Republic of Ireland
    Eur J Surg Oncol 29:20-4. 2003
    ..The aim of this study was to validate the aforementioned system against the commonly used methods of assessing oestrogen receptor status...
  66. pmc Plasminogen activator inhibitor type 2 in breast cancer
    C Duggan
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Br J Cancer 76:622-7. 1997
    ..However, using an optimum cut-off value, patients with low levels of PAI-2 had a worse outcome than those with a high level. We conclude that, unlike PAI-1, high levels of PAI-2 may be a favourable prognostic marker in breast cancer...
  67. ncbi request reprint Ets2 transcription factor in normal and neoplastic human breast tissue
    Y Buggy
    UCD School of Medicine and Medical Science, Conway Institute of Biomolecular and Biomedical Research, Dublin 4, Dublin, Ireland
    Eur J Cancer 42:485-91. 2006
    ..43, P = 0.0005, n = 68; for p54, r = 0.50, P = 0.0001, n = 68). As Ets2 binding sites are present on the uPA promoter, Ets2 may be one of the transcription factors regulating uPA expression in human breast cancer...
  68. ncbi request reprint Estrogen receptor-beta mRNA is associated with adverse outcome in patients with breast cancer
    G C Markey
    Conway Institute of Biomolecular and Biomedical Research, UCD School of Medicine and Medical Science, University College Dublin, Dublin, Ireland
    Tumour Biol 30:171-5. 2009
    ..Both forms may be expressed in breast cancer. The aim of this study was to examine breast cancer outcome in relation to expression of ER-beta...
  69. ncbi request reprint Expression of Cathepsin B and L antigen and activity is associated with early colorectal cancer progression
    A M Troy
    Centre for Colorectal Disease, St Vincent s University Hospital, Elm Park, Dublin 4, Ireland
    Eur J Cancer 40:1610-6. 2004
    ..007) and L (P = 0.001) activity ratio, in addition to cathepsin L antigen ratio (P = 0.008). Our findings suggest that cysteine proteases play an important role in colorectal cancer progression...
  70. ncbi request reprint Urokinase plasminogen activator: a prognostic marker in multiple types of cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, University College of Dublin, Ireland
    J Surg Oncol 71:130-5. 1999
    ..uPA is also prognostic in other malignancies, such as gastric, colorectal, esophageal, renal, endometrial, and ovarian cancers. uPA may thus be a prognostic indicator for multiple types of adenocarcinoma...
  71. ncbi request reprint CA 15-3: a prognostic marker in breast cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, Dublin, Ireland
    Int J Biol Markers 15:330-3. 2000
    ..Furthermore, in multivariate analysis the prognostic impact of CA 15-3 was stronger than that of tumor size and at least as strong as nodal status. CA 15-3 may thus be the first independent prognostic serum marker in breast cancer...
  72. ncbi request reprint Clinical uses of tumor markers: a critical review
    M J Duffy
    Department of Nuclear Medicine, St Vincent s University Hospital, and University College Dublin, Ireland
    Crit Rev Clin Lab Sci 38:225-62. 2001
    ..In general, the currently available tumor markers lack sensitivity for early cancer and specificity for malignancy. The goal of future research should be to develop more sensitive and specific markers, especially for the common cancers...
  73. ncbi request reprint ADAM-17 predicts adverse outcome in patients with breast cancer
    P M McGowan
    Department of Pathology, Laboratory Medicine, Conway Institute, University College Dublin, Dublin 4, Ireland
    Ann Oncol 19:1075-81. 2008
    ..Our results are further evidence that ADAM-17 is involved in breast cancer progression and thus provides further impetus for exploiting ADAM-17 as new target for cancer treatment...
  74. pmc Assay of matrix metalloproteases types 8 and 9 by ELISA in human breast cancer
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Br J Cancer 71:1025-8. 1995
    ..MMP-8 but not MMP-9 levels were also inversely correlated with progesterone receptor levels. It is concluded that the assay for MMP-8 and -9 described here will permit the evaluation of these proteases as prognostic markers in cancer...
  75. pmc Elevated expression and altered processing of fibulin-1 protein in human breast cancer
    L M Greene
    Department of Pharmacology, Conway Institute of Biomolecular and Biomedical Research, University College Dublin, Belfield, Ireland
    Br J Cancer 88:871-8. 2003
    ..003, n=36) and progesterone receptor (rs=0.43, P=0.008, n=36) expression in the tumour specimens. Taken together, these findings indicate that elevated expression and altered processing of fibulin-1 is associated with human breast cancer...
  76. ncbi request reprint Urokinase plasminogen activator: a prognostic marker in breast cancer including patients with axillary node-negative disease
    M J Duffy
    Department of Nuclear Medicine, St Vincent s Hospital, Dublin, Ireland
    Clin Chem 44:1177-83. 1998
    ..Measurement of uPA concentrations might thus be of value in selecting the more aggressive subpopulation of node-negative breast cancer patients that could benefit from adjuvant therapy...
  77. pmc Semi-quantitation of urokinase plasminogen activator and its receptor in breast carcinomas by immunocytochemistry
    S Kennedy
    Department of Pathology, Royal Victoria Eye and Ear Hospital, Dublin, Ireland
    Br J Cancer 77:1638-41. 1998
    ..We conclude that both uPA and its receptor are mostly present in stromal cells in invasive breast carcinomas. These results suggest that stromal cells collaborate with malignant cells to mediate metastasis...
  78. ncbi request reprint Tumor-associated alterations in caspase-14 expression in epithelial malignancies
    Maryla Krajewska
    The Burnham Institute, La Jolla, California, USA
    Clin Cancer Res 11:5462-71. 2005
    ..We investigated caspase-14 expression in several types of human epithelial malignancy by immunohistochemistry, correlating results with stage, histologic grade, and patient survival...
  79. ncbi request reprint Matrix metalloproteinase 26 proteolysis of the NH2-terminal domain of the estrogen receptor beta correlates with the survival of breast cancer patients
    Alexei Y Savinov
    The Burnham Institute, La Jolla, California 92037, USA
    Cancer Res 66:2716-24. 2006
    ....
  80. ncbi request reprint Tumor markers in breast cancer- European Group on Tumor Markers recommendations
    Rafael Molina
    Laboratory of Biochemistry, Hospital Clinic, Medical School, Barcelona, Spain
    Tumour Biol 26:281-93. 2005
    ....
  81. ncbi request reprint Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients
    Maxime P Look
    Department of Medical Oncology, University Hospital Rotterdam, The Netherlands
    J Natl Cancer Inst 94:116-28. 2002
    ....
  82. pmc Bcl-B expression in human epithelial and nonepithelial malignancies
    Maryla Krajewska
    Burnham Institute for Medical Research, La Jolla, California 92037, USA
    Clin Cancer Res 14:3011-21. 2008
    ..Bcl-B is an antiapoptotic Bcl-2 family member, which is known to change its phenotype upon binding to Nur77/TR3. The expression pattern of this protein in human malignancies has not been reported...